Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Safety, Efficiency of Pembrolizumab Monotherapy in Geriatric PD-L1+ NSCLC

  • Leanne Marcello, MS
October 16, 2019
  • Lung Cancer, Cancer, News

Scientists from around the globe recently came together to conduct a pooled analysis of safety and efficacy of the programmed death 1 inhibitor, pembrolizumab in patients 75 years of age or older diagnosed with advanced non–small-cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1)‒positive tumors. The analysis was based on the KEYNOTE-010, -024, and -042 studies.

The researchers concluded that pembrolizumab improved survival when compared with chemotherapy for PD-L1‒positive advanced NSCLC. They observed no unexpected toxicity from pembrolizumab in patients 75 year of age or older, and outcomes for this group were similar to those in the overall study population.

Most lung cancer diagnoses occur in elderly patients, and yet this population is underrepresented in clinical trials, making this analysis important for the majority of NSCLC patients. The geriatric population has a greater number of tolerability issues due to impaired reduced cognitive, cardiac or renal function, or other comorbidities. Other studies have noted that side effects and treatment discontinuation rates are higher among advanced NSCLC patients who are 70 years of age or older and undergoing platinum-based chemotherapy.

The retrospective and exploratory pooled analyses examined patients ages 18 years or older from the KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894) studies, who had advanced NSCLC with PD-L1–positive tumors.

Patients in KEYNOTE-010 were randomized to either pembrolizumab—2mg/kg or 10 mg/kg—every 3 weeks (Q3W), or to docetaxel as second-line or later therapy. Patients in KEYNOTE-024 and KEYNOTE-042 were randomized to either first-line pembrolizumab 200 mg Q3W, or platinum-based chemotherapy. Researchers detailed safety data and estimated overall survival (OS) by the Kaplan-Meier method.

In all, 264 elderly patients with PD-L1–positive tumors (PD-L1 tumor proportion score [TPS] ≥1%) were analyzed. Of this total, 132 had PD-L1 TPS ≥ 50%. Pembrolizumab improved OS in patients 75 years of age or older who had PD-L1 TPS ≥ 1% (hazard ratio [HR], 0.76 [95% CI, 0.56–1.02]) and PD-L1 TPS ≥ 50% (HR, 0.40 [95% CI, 0.25–0.64]). Used a first-line therapy, pembrolizumab also improved OS among elderly patients with PD-L1 TPS ≥ 50% (from KEYNOTE-024 and KEYNOTE-042) when compared with chemotherapy (HR, 0.41 [95% CI, 0.23‒0.73]). The extent of benefit with pembrolizumab increased concurrent with rising levels of PD-L1 expression.There appeared to be fewer treatment-related adverse events (AEs) associated with pembrolizumab versus chemotherapy used in the geriatric population (overall, 68.5% vs 94.3%; grade ≥3, 24.2% vs 61.0%). Both immune-mediated AEs as well as infusion reactions were more likely with a pembrolizumab regime than with those using chemotherapy (overall, 24.8% vs 6.7%; grade 3‒4: 9.4% vs 0%; no grade 5 events).

Compared with chemotherapy, pembrolizumab had a greater safety profile in elderly patients with advanced NSCLC and PD-L1‒positive tumors, and resulted in a more favorable prognosis. Furthermore, older age was not associated with increased toxicity from pembrolizumab therapy than was seen in younger populations.

Related Articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".